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ABI – abortive infection 
AD – Alzheimer’s disease 
Aph1 – anterior pharynx defective 1 
APP – amyloid-β (Aβ) precursor protein 
AtRBL – Arabidopsis thaliana rhomboid-like proteases 
BCAM – basal cell adhesion molecule 
COP – coat protein complex 
DCBLD2 – CUB (complement C1r/C1s, Uegf, Bmp1) and LCCL (Limulus clotting factor C,  
Cochlin and Lgl1) domain-containing protein 2 
DDR1 – discoidin domain-containing receptor 1  
Der1 – degradation in the endoplasmic reticulum protein 1 
EGF – epidermal growth factor 
ER – endoplasmic reticulum 
ERAD – ER-associated degradation 
FCCS – fluorescence cross-correlation spectroscopy  
FRET – Förster resonance energy transfer 
GPMV – giant plasma membrane vesicle 
IFAP – ichthyosis follicularis alopecia photophobia 
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IMPRs – intramembrane proteases 
KIRREL1 – Kin of irregular chiasm-like protein 1 
MBP – maltose binding protein 
MC – Monte Carlo 
PARL – presenilins-associated rhomboid-like protein 
Pen2 – presenilin enhancer 2 
PGAM5 – phosphoglycerate mutase 5 
PINK1 – PTEN (phosphatase and tensin homolog) - induced kinase 1 
PS1 – presenilin 1 
PS2 – presenilin 2 
Rce1 – Ras converting CAAX endopeptidase 1 
RIP – regulated intramembrne proteolysis 
S1P – site-1 protease 
S2P – site-2 protease 
SCAP – SREBP cleavage-activating protein 
SPP – signal peptide peptidase 
SPPLs – signal peptide peptidase like proteases 
SREBP – sterol regulatory element-binding protein 
Tat (pathway) – twin-arginine translocation pathway 
TMH – transmembrane helix 
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2 Abstract 
Intramembrane proteases from the rhomboid-like superfamily are enzymes widely 
distributed and conserved in all domains of life. They participate in many important processes 
such as membrane protein quality control or mitochondrial dynamics. Their activity is also 
linked with diseases like Parkinson’s disease or cancer. This makes them potential therapeutic 
targets. In this work we tried to elucidate in more detail the mechanism of action of the main 
model intramembrane protease, GlpG from E. coli. We also focused on the mechanism of 
eukaryotic rhomboid RHBDL2, one of the four mammalian rhomboids, function of which is 
poorly understood. To acquire more detailed information about substrate-enzyme interaction, 
we synthesized a series of novel peptidyl-chloromethylketone inhibitors derived from natural 
rhomboid substrate TatA from P. stuartii. Crystal structure of the complex of GlpG with these 
inhibitors revealed four substrate binding subsites (S1 to S4) of the enzyme and explained its 
observed substrate specificity structurally. This study showed that substrate cleavage rate can 
be dramatically modified by changing the substrate sequence in positions P1 to P5. This 
helped us develop fluorogenic transmembrane peptide substrates for rhomboid proteases, 
which are usable in detergent and liposomes, and compatible with high-throughput screening. 
Using these substrates we showed that rhomboid proteases require almost the entire 
transmembrane domain of the substrate for efficient recognition and cleavage, and the enzyme 
probably interacts with the transmembrane domain of the substrate via a membrane-immersed 
exosite. Based on this knowledge we have designed novel and potent rhomboid inhibitors 
based on peptidyl-α-ketoamides. These compounds are active at nanomolar concentrations, 
and are selective for rhomboids. Crystal structures revealed that peptidyl-α-ketoamides bind 
the rhomboid covalently by mimicking the tetrahedral intermediate. Finally, by employing 
advanced fluorescence spectroscopy techniques (FRET and FCCS), we have investigated the 
behavior of the rhomboid protease RHBDL2 in a natural biomembrane. While it was 
previously thought that rhomboids are allosterically activated by dimerization, we found no 
evidence of RHBDL2 dimerization in natural membranes. Importantly, the approaches 
developed in this work are generally applicable to the assessment of dimerization of 
transmembrane proteins. In summary, the findings described in this thesis significantly 
contribute to the understanding of the mechanism of action of rhomboid proteases.   
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3 Abstrakt 
Intramembránové proteasy z rodiny rhomboidů jsou v přírodě široce rozšířeny 
a vyskytují se ve všech doménách života. Podílejí se na mnoha důležitých procesech, jako 
například kontrola kvality membránových proteinů nebo mitochondriální dynamika. Jejich 
aktivita souvisí s nemocemi jako Parkinsonova nemoc nebo rakovina. Proto se rhomboidy jeví 
jako potenciální terapeutické cíle. V této práci jsme se snažili objasnit detailní mechanismus 
fungování modelové proteasy GlpG z E. coli. Zaměřili jsme se i na mechanismus rhomboidu 
RHBDL2, což je jeden ze čtyř eukaryotických rhomboidů, jejichž funkce není příliš 
prostudována. Pro pochopení vazby mezi substrátem a enzymem jsme připravili řadu nových 
peptidyl-chlormethylketonových inhibitorů odvozených od proteinu TatA, což je substrát 
rhomboidu v P. stuartii. Díky krystalové struktuře komplexů GlpG s těmito inhibitory jsme 
prozkoumali vazebná místa substrátu S1 až S4, což nám umožnilo objasnit strukturní podstatu 
substrátové specifity enzymu. Ukázali jsme, že rychlost štěpení substrátu může být významně 
ovlivněna modifikací sekvence substrátu na pozicích P1 až P5. Na základě těchto pozorování 
jsme vyvinuli fluorogenní transmembránový peptidový substrát rhomboidových proteas, který 
je použitelný jak v detergentu, tak v liposomech, a je vhodný pro testování s vysokou 
propustností. Pomocí těchto substrátů jsme dokázali, že rhomboidy pro efektivní zpracování 
substrátu vyžadují takřka kompletní transmembránovou část substrátu a že interakce mezi 
enzymem a substrátem nejspíš probíhá uvnitř membrány. Díky těmto znalostem se nám 
podařilo navrhnout silné inhibitory proteas z rodiny rhomboidů, jejichž základem jsou 
peptidyl-α-ketoamidy. Tyto inhibitory jsou aktivní v nanomolárních koncentracích a působí 
selektivně na proteasy z rodiny rhomboidů. Pomocí krystalových struktur jsme prokázali, že 
vazba peptidyl-α-ketoamidu na rhomboid je kovalentní, podobná tetraedrálnímu meziproduktu 
štěpení substrátu. Pomocí pokročilých metod fluorescenční spektroskopie (FRET a FCCS) 
jsme objasnili chování rhomboidové proteasy RHBDL2 v jejím přirozeném prostředí. Zatímco 
dosavadní výsledky naznačovaly možnost alosterické aktivace rhomboidů jejich dimerizací, 
my jsme nenašli žádné důkazy o dimerizaci RHBDL2 v bimembráně. Během této práce se 
nám podařilo vyvinout metodiku široce aplikovatelnou na studium dimerizace membránových 
proteinů. Všechny poznatky popsané v této práci významně přispívají k pochopení 




Proteases have been studied by scientists for decades. They are involved in many 
complicated biological processes like apoptosis, wound healing, angiogenesis, cell migration 
and differentiation, tissue remodeling, neuronal outgrowth, hemostasis, morphogenesis and 
immunity [1], and their activity is also linked to many pathological conditions, 
neurodegenerative and cardiovascular diseases, cancer, arthritis and progeria [2]. One of the 
first discovered enzymes, the digestive protease pepsin (1836, Theodor Schwann), was also 
one of the first enzymes crystallized (1928, John H. Northrop). Moreover, the first X-ray 
diffraction pattern of a protein was acquired in 1934 using pepsin crystals [3]. Nowadays, 
many proteases are intensively studied as potential therapeutic targets [4] and biotechnological 
tools [5]. Based on the mechanism of their action, proteases are grouped into four main 
families: serine, cysteine, aspartyl and metalloproteases (Figure 1), with some specialized 
mechanistic variations, such as threonine peptidases (proteasomes). When cleaving 
a substrate, aspartyl proteases and metalloproteases use activated water molecule to attack the 
peptide bond, while cysteine and serine protease use water molecule to resolve a covalent 
intermediate formed between the enzyme and the substrate in the first step of catalysis.  
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Figure 1: Schematic representation of the catalytic action of the four protease families. Serine 
proteases (a) have a catalytic triad (serine, histidine and aspartic acid). The hydroxyl group of 
serine acts as a nucleophile attacking the carbonyl of the peptide bond of the substrate, the 
nitrogen of histidine with a free electron pair can accept a proton from the hydroxyl group of 
serine, and the aspartic acid renders the nitrogen of histidine even more electronegative. 
A covalent intermediate between the enzyme and substrate occurs during the reaction. 
Cysteine proteases (b) also use nucleophile attack, in this case performed by the negatively 
charged sulfur of the catalytic cysteine, also including the enzyme – substrate covalent 
intermediate. Aspartyl proteases (c) have two aspartic acid residues coordinating a water 
molecule. In this case, the covalent intermediate does not occur and the proteolysis is 
performed in a single step. Metalloproteases (d) are the most variable protease family. In these 
enzymes, a coordinated metal, usually zinc, activates the catalytic water molecule. Adopted 
from [6]. 
 
4.2 Intramembrane proteolysis 
Proteolysis within the membrane was first reported as an essential process in sterol 
homeostasis [7]. In the Golgi apparatus, the cytoplasmic domain of the mammalian sterol 
regulatory element-binding protein (SREBP) is cleaved off from the membrane domain by an 
intramembrane metalloprotease, later classified as a member of the site-2 protease (S2P) 
family, (reviewed in [8]). The liberated domain can then relocate to the nucleus and activate 
genes responsible for the synthesis of cholesterol and fatty acids [9]. This discovery 
established the principles of intramembrane proteolysis and since then, more intramembrane 
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proteases (IMPRs) have been identified and classified into three major groups based on their 
similarities: S2P zinc metalloproteases, rhomboid serine proteases, aspartyl IMPRs signal 
peptide peptidases (SPP) and presenilin. These major families are complemented by the 
recently discovered glutamate intramembrane proteases homologous to the Ras converting 
enzyme Rce1 [10]. In summary, intramembrane proteolysis (also called regulated 
intramembrane proteolysis, or RIP) is a process highly conserved from bacteria to mammals. 
RIP has an important role in many cellular processes like proliferation [11], differentiation [9], 
protein degradation [12], cell adhesion [13], lipid metabolism, transcriptional regulation and 
mitophagy [14]. 
 
4.2.1 Biological substrates and functions of IMPRs 
More than 100 transmembrane protein substrates undergo RIP; these include growth 
factors and their receptors, cytokines and their receptors, cell adhesion proteins, viral proteins 
and signal peptides [15–17]. Among the most studied substrates of intramembrane proteases 
(IMPRs) are amyloid-β precursor [18], Notch [19,20], E-cadherin [13], tumor necrosis factor  
[21], interleukin-1 receptor type I and II [22–24], insulin-like growth factor 1 receptor [25], 
epidermal growth factor [26], receptor tyrosine kinase ErbB4 [27], p75 neurotrophin receptor 
[28–30], CD44 [31], triggering receptor expressed on myeloid cells-2 [32] and epithelial cell 
adhesion molecule [33]. Based on the wide diversity of substrates, RIP is proposed to be 
associated with many important physiological processes, such as haematopoiesis, embryonic 
development and regulation of nervous and immune systems, (reviewed in [34]).  
IMPRs have very diverse sequences and even proteases from the same family and the 
same organism can have relatively low sequence similarity. Homologous IMPRs can also have 
diverse functions and different substrate(s) in different species, cells and organelles. On the 
other hand, it is known that some proteases can cleave synthetic model substrates or non-
natural substrates from different organisms [35,36]. In principle, an IMPR substrate can be 
cleaved in three regions with respect to its membrane topology: close to one of the edges of 
the substrate TMH, which results in the release one of the products from the membrane, or 
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towards the substrate TMH center, which induces liberation of both cleavage products from 
the membrane. Each of these scenarios has different purpose and is related to the function of 
the substrate (see Figure 2) [37].  
 
Figure 2: Three possible scenarios of transmembrane protein cleavage by an IMPR: (A) 
cleavage in the middle of the substrate’s membrane region results in the dislocation of both 
cleavage product stubs from the hydrophobic environment of the lipid membrane; (B), (C) 
cleavage closer to the edge of the substrate’s membrane region causes dislocation of only one 
of the products from the membrane. Adopted from [37]. 
 
Most IMPR substrates are transmembrane proteins with a single TMH, typically (but 
not always) containing a helix-destabilizing motif [9,38]. In some cases, insertion of a 
destabilizing amino acid residue such as Gly or Pro can even turn some non-substrates into 
substrates [39]. This indicates that IMPRs require substrates with helically unstable region(s), 
typically having one transmembrane segment, although IMPRs have been shown to cleave 
also polytopic membrane proteins [40,41]. Furthermore, some IMPRs do not require the 
destabilizing residues for substrate cleavage [42,43] and other IMPR substrates were shown to 
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have a tightly packed α-helix in the cleavage site [44,45]. All these facts together imply that 
RIP is a complex process and more research is required to understand it sufficiently well. 
  
4.2.2 Site-2 proteases 
Site-2 proteases (S2Ps) constitute a large family of intramembrane metalloproteases. 
They participate in the maturation of transcription factors, and usually require pre-cleavage of 
their substrate by another protease (also sometimes called S1P) [8,9,46]. As already 
mentioned, the first discovered IMPR was an S2P protease [7]. Its substrate, sterol regulatory 
element-binding protein (SREBP) – an intramembrane transcription factor, moves from the 
ER (in complex with SREBP cleavage-activating protein (SCAP)) to the Golgi apparatus via 
coat protein complex II (COP II) coated vesicles when the cell needs to synthetize more lipids. 
In the Golgi, two different proteases process this substrate in tandem. S1P cleaves SREBP in a 
luminal loop between its two TMHs; only the product of this cleavage can become a substrate 
of S2P [47] (see Figure 3). S2P homologs have also been identified in archaea [48] and 
prokaryotes [49], which shows that S2P proteases are evolutionarily very old. A mutation in 
human S2P is associated with the ichthyosis follicularis, alopecia and photophobia (IFAP) 
syndrome [50].  
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Figure 3: Schematic representation of SREBP cell fate. Adopted from [51]. 
As for other intramembrane proteases, it is difficult to fully understand the mechanism 
of action of S2Ps, because the substrate hydrolysis occurs in the membrane [48]. All the 
known S2P substrates are transcription factors with at least one type II TMH [52], which is the 
site of cleavage by S2P [50]. 
 
4.2.3 Aspartyl intramembrane proteases 
 
Presenilins 
Presenilins are key components of the γ-secretase complex whose activity is related to 
the pathogenesis of Alzheimer’s disease (AD) [53–55], the most common neurodegenerative 
disease leading to dementia with no efficient treatment available so far. Gamma secretase is 
responsible for the cleavage of Amyloid-β (Aβ) precursor protein (APP) which contributes to 
the formation of toxic amyloid-β peptides which then aggregate into senile plaques [56]. There 
are two presenilin genes, PSEN1 and PSEN2, mutations of which are related to AD [57]. 
These genes encode polytopic membrane proteins presenilin 1 (PS1) and presenilin 2 (PS2), 
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respectively [58], which exhibit 67% sequence identity [59]. PS1 is a protein with 9 TMH, 
which contains two catalytic aspartate residues on TMH 6 and 7 (Figure 4:) and is localized 
mostly in ER and Golgi. Presenilins are synthesized in the form of inactive zymogens and 
have to be activated by endoproteolysis [60].  
 
 
Figure 4: Schematic picture of PS1 protein topology with catalytic residues in green and 
mutations linked to AD in red. Adopted from [61]. 
  
Apart from presenilin, the γ-secretase complex contains three other components 
(Figure 5). Nicastrin helps with substrate recruitment [62], anterior pharynx defective 1 
(Aph1) is an essential cofactor [63] and presenilin enhancer 2 (Pen2) subunit is important for 
proper complex maturation [64]. The stoichiometry of the subunits in the γ-secretase complex 




Figure 5: The γ-secretase complex with its subunits. Adopted from [55]. 
 
The γ-secretase complex has many substrates of various physiological functions, 
structure and localization. These are usually type I membrane proteins [66] responsible for 
signaling and regulation of cellular processes such as adhesion or migration. The complex also 
usually prefers membrane protein substrates after the shedding of ectodomains, rather than 
full-length proteins [67]. A total of 80 γ-secretase substrates have been identified so far, but 
the two most important and most studied substrates are the already mentioned APP and also 
Notch, a protein important for intercellular communication, gene regulation and cell 
differentiation [68]. 
 
Signal peptide peptidase like proteases (SPPLs) 
Apart from eukaryotic organisms, presenilin homologs have been found also in 
organisms that do not possess other components of γ-secretase, including archaea [69], 
indicating that they represent members of a larger family of aspartyl IMPRs. In fact, other 
members of this family of IMPRs were discovered in 2002 using bioinformatics and 
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biochemical methods by three independent groups. They found that SPP and its homologs 
form a cluster of aspartyl IMPRs closely related to presenilins and that they share a conserved 
motif YD and LGLGD within their catalytic center (Figure 6). The family of SPP and SPP-
like proteases (SPPLs) is conserved among eukaryotes, including protozoa, fungi, plants and 
animals [69–71]. Although these proteins share a similar architecture, they have evolved 
different physiological functions in different species [72]. SPPLs are localized in ER [73], 
Golgi [74] and lysosomes [75], but they can also occur on plasma membrane [76].  
 
 
Figure 6: A model of SPP with the two catalytic aspartates in the YD and LGLGD motifs. 
Adopted from [77]. 
 
The name of SPPLs is derived from the ability of the founding member SPP to cleave 
signal peptides. However, SPPL substrates are much more diverse. For example, they play 
role in the immune system [78], participate in protein post-targeting [79], and their activity is 
important for maintaining membrane homeostasis [80]. Their substrates usually have to be 
pre-cleaved by other proteases (Figure 7) [72] and, despite their similarity to presenilins, they 








The class of glutamate IMPs is represented by a recently identified intramembrane 
protease Rce1 located in the ER. The overall structure of Rce1 with eight TMHs and also the 
catalytic site of this enzyme are distinct from the other IMPs, which makes Rce1 a founding 
member of a new IMP family [10]. Rce1 is also a member of the ABI (abortive infection) 
family of putative IMPRs. These proteins are involved in membrane protein anchoring in 
eukaryotes and their homologues in prokaryotes are probably involved in bacteriocin self-
immunity [82]. It has been shown that Rce1 inactivation in mice leads to mislocalization of 
Ras proteins from the plasma membrane [83], development of lethal dilated cardiomyopathy 
[84], and it also interferes with the survival of photoreceptor cells in mice [85]. 
 
4.3 Rhomboids 
The name of the rhomboid family of intramembrane proteases originates from the first 
discovered member – rhomboid-1 from Drosophila melanogaster. Mutations of the rhomboid-
1 gene interfere with grow factor signaling [86] and result in a characteristically changed,  
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pointed head skeleton of the fly [87]. Since then rhomboids and their homologs have been 
identified in all domains of life and they are the most abundant and widespread family of 
IMPRs [88]. Interestingly, several psuedoproteases (i.e. proteolytically inactive proteins) show 
topological similarity to rhomboid proteases, such as iRhoms [89] and Derlins [90]. The usage 
of the term ‘rhomboid-like’ protein superfamily (Figure 8 and Figure 16) is then probably 
more accurate than using just the simple ‘rhomboid’ family [91].  
 
Figure 8: Classification of the rhomboid-like superfamily. The rhomboid-like cluster of 
proteins has been classified based on functional and sequence relationships [91], but this 
scheme does not represent evolutionary relations. Adopted from [91]. 
 
4.3.1 Rhomboid mechanism of action 
It was initially very controversial whether proteolysis could be possible in a hydrophobic 
lipid environment. The research into rhomboid protease mechanism of action has revealed 
many details of how this may be possible. Rhomboid proteases have a catalytic dyad instead 
of the classical triad and the catalytic serine residue is hidden in a water-accessible pocket 
created by TMH’s of the protease, which protects it from the lipid environment. This progress 
was possible mostly thanks to the reconstitution of rhomboid activity in vitro [90,92], and to 
the solving of high resolution X-ray crystallographic structures (Figure 9) of  the model E. coli 
rhomboid protease GlpG (Figure 10) [93–95], which was the first structure of an 
intramembrane protease.  
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Figure 9: A ribbon diagram of the E. coli rhomboid protease GlpG crystal structure in three 
orientations. Adopted from [93]. 
 
 
Figure 10: Schematic representation of a model rhomboid protease from E. coli:  GlpG. The 
color code corresponds to Figure 9. Adopted from [93]. 
 
X-ray crystallography also suggested how the substrate may enter the active site of 
rhomboid. Crystallographic analysis of E. coli GlpG revealed alternative ‘open’ conformations 
of TMH5, which led to the proposal that a lateral ‘substrate gate’ is formed by TMH 2 and 5 
of the protease [89]. This was confirmed by enzymatic [96] and biophysical [97] analyses. 
Similar structural disorder was detected also in the homologous H. influenzae GlpG [98]. The 
details of this mechanism are debated, such as whether lateral movement of TMH5 is really 
required for substrate cleavage by GlpG [99], or whether TMH2 and 5 just form an 
intramembrane binding site (an ‘exosite’) recognizing the TMH of the substrate. This substrate 
entry route is nevertheless strongly supported by the most recent observations [100]. 
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Other efforts focused on the analysis of rhomboid protease substrates and their features 
important for the recognition by rhomboids. The influence of the biophysical properties of 
substrate TMH (Figure 11A) on rhomboid activity was studied in detail [101], and the results 
confirmed the importance of helix-destabilizing residues (see also section 4.2.1). Other 
research revealed that the cleavage site and rate are determined by a ‘recognition motif’ region 
between positions P4 and P2’ (Figure 11B) [102]. A unifying picture emerges that rhomboid 
substrates are defined by two elements, a transmembrane region interacting with the rhomboid 
inside the membrane, and a recognition motif that interacts with the water-accessible active 
site of rhomboid. These two elements may require flexibility between them, which may be 
conferred by the helix-destabilizing residues. Because of the sequence diversity in the 
rhomboid-like superfamily, it is highly unlikely that a more exact common substrate-
determining rule will be found. Rhomboid substrate specificity is probably driven by both 
mentioned elements with different contributions depending on the particular substrate [91]. 
According to some authors, rhomboid mechanism of action is also affected by their specific 
three-dimensional shape (Figure 12), which can bias surrounding lipids (and thus also protein 




Figure 11: Schematic representation of rhomboid protease substrate specificity. (A) Sequence 
alignment of rhomboid substrate TatA TMD truncated variants and efficiency of their 
cleavage by bacterial rhomboid protease AarA. The enzyme requires a certain TMD length for 
efficient action. (B) Positional scanning mutagenesis of P5 to P2’ sites of TatA, the natural 
substrate of bacterial rhomboid protease AarA. The mutations are ranked into four grades 
based on the severity of their effect on cleavage efficiency (depicted in shades of grey). 
Residues in positions P1, P4 and P2’ in the substrate TatA had the biggest impact on cleavage 




Figure 12: Lipid reorientation around the full-length rhomboid protease GlpG (red) induced 
by the rhomboid shape, and in the case of GlpG also affected by its N-terminal domain 
(orange: GlpG without the N-terminal domain). A standard membrane protein (purple) does 
not affect the arrangement of surrounding lipids. The diffusion coefficient of proteins is 
dependent on their shape (graph). Adopted from [103].  
 
4.3.2 Biological role of selected rhomboid proteases in different species 
Rhomboid proteases are present in all domains of life, and during evolution they 
presumably adopted widely different roles in different biological processes, from regulating 
protein secretion in bacteria to mitochondrial dynamics in eukaryotes [104–107]. Their 
activity has also been associated with pathological processes including cancer [108] and 
Parkinson’s disease [109]. 
 Despite the wide distribution of rhomboids in bacteria, with some bacteria containing 
more than one rhomboid, very little is known about their biological function in prokaryotic 
cells [110]. The best studied bacterial rhomboid from the functional point of view is the 
rhomboid AarA in Providencia stuartii. AarA is responsible for processing the TatA protein, 
thereby activating the twin-arginine translocation (TAT) pathway. TatA is activated by the 




Figure 13: Model of TAT system activation in P. stuartii by the AarA rhomboid protease. 
The TatA protein can interact with the other subunits of the Tat system (TatB and TatC) only 
after its N-terminal extension is removed by the AarA rhomboid. Active Tat system is 
responsible for quorum sensing signal transmission by an unknown mechanism. Adopted from 
[110]. 
  
The E. coli rhomboid GlpG was identified in 2002 [35]. The gene coding for this 
enzyme is a member of the glpEGR operon, the function of which is associated with glycerol 
metabolism via glpR [112]. GlpG is the main model rhomboid for structural (Figure 10) and 
functional studies [97], but its natural substrates and its role in E. coli metabolism remain 
unknown [36,113,114]. GlpG can utilize a variety of model rhomboid substrates [35] ranging 
from bacterial to eukaryotic proteins, typically embedded in a hybrid scaffold composed of the 
substrate transmembrane region (e.g. of LacY, TatA, Gurken or Spitz) fused to a periplasmic 
maltose-binding protein domain and a cytoplasmic thioredoxin domain [102]. It was proposed 
that GlpG and two other bacterial rhomboid proteases are allosterically activated by 
dimerization, and allosteric regulation by dimerization has been suggested to potentially be a 
general property of rhomboid proteases [115]. However, this theory is in contrast with our 
own observation (see section 6.4), which is also supported by recently published independent 
research [116]. 
Plants contain a larger number of rhomboids than animals [117], but their biological 
roles are largely unknown. The exception are AtRBL8 and AtRBL9, which are probably 
responsible for flower development in Arabidopsis thaliana [118]. 
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The roles of rhomboid proteases in eukaryotic parasites are understood relatively well. 
They participate in adhesion and invasion of apicomplexan parasites such as Toxoplasma 
gondii and Plasmodium falciparum [39], and for this reason they are investigated as potential 
therapeutic targets [119]. Their roles in other parasites such as Cryptosporidium are being 
studied [120].  
Mitochondrial rhomboids constitute a special sort of eukaryotic rhomboids [121]. They 
are located in the inner mitochondrial membrane and participate in membrane remodeling in 
Saccharomyces cerevisiae [122] and membrane dynamics in Drosophila melanogaster [123]. 
Mouse mitochondrial rhomboid PARL and one of its substrates, PINK1 (Figure 14), are 
studied for their possible implication in Parkinson’s disease [109]. Other PARL substrate, 
PGAM5, has been linked to apoptosis and sensing of mitochondrial damage [124]. PARL 
activity is influenced by mitochondrial membrane potential, possibly via translocation and 
topological effects on its substrates (Figure 14) [124]. 
 
 
Figure 14: Proposed model of mitochondrial membrane dependent regulation of PARL-
mediated cleavage of PINK1 and PGAM5. Adopted from [124]. 
 
Beside rhomboids in mitochondria, there are four other proteases of the rhomboid 
family in mammalian cells: RHBDL1 – 4 [125], all localized within the secretory pathway 
[40]. Their functions are poorly understood. RHBDL4 is localized to the endoplasmic 
reticulum (ER), the compartment where membrane and secretory proteins fold. RHBDL4 has 
only 6 TMHs, unlike the other RHBDLs, which have 7 TMHs (Figure 15 and Figure 16) 
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[125]. RHBDL4 is upregulated by ER stress, suggesting that it could act as a quality control 
protease [40]. Indeed, it has been shown to interact with p97/VCP, degrade some aberrant 
membrane proteins with unstable helices, and to participate in the process of ER-associated 
degradation (ERAD) [40]. A huge step forward was recently made in the identification of 
natural substrates of RHBDL2. Proteomics analysis showed that RHBDL2 cleaves several 
novel substrates including the interleukin-6 receptor, cell surface protease inhibitor Spint-1, 
the collagen receptor tyrosine kinase epithelial discoidin domain-containing receptor 1 
(DDR1), N-cadherin, discoidin, CUB and LCCL domain-containing protein 2 (DCBLD2), Kin 
of IRRE-like protein 1 (KIRREL1), basal cell adhesion molecule (BCAM) and others [126]. 
The identified substrate repertoire and epithelial expression implicates RHBDL2 in epithelial 
homeostasis [126]. 
 
Figure 15: A phylogenetic tree of human rhomboid family proteins in the secretory pathway. 
Active rhomboid proteases and inactive pseudoproteases are highlighted in red and black, 
respectively. The comparison of similarity is based on the conserved regions (loop 1 and 




Figure 16: Schematic representation of the evolutionary relationship within the ‘rhomboid-
like superfamily’. E. coli (Ec) rhomboid GlpG is compared with members of the rhomboid-
like superfamily from different species: Homo sapiens (Hs), Drosophila melanogaster (Dm) 
and Saccharomyces cerevisiae (Sc). Conserved six-pass TMH core is depicted in blue, with 
possible extra domain in red. The typical motif of the rhomboid active site (GxSG and H) and 
the L1 loop extension in the membrane (WR) are indicated and the GPxG motif typical for 
iRhoms is also shown. Presumable evolutionary relationships between members of the 
‘rhomboid-like superfamily’ are represented by arrows. Adopted from [127]. 
 
The most important representatives of the proteolytically inactive rhomboid-like 
proteins are iRhoms and Derlins. iRhoms are phylogenetically closely related to active 
rhomboids (Figure 15). In comparison with active rhomboids, they have a slightly altered 
architecture with a large insertion into the L1 loop (Figure 16) [127] and they lack catalytic 
activity [89]. Their function is related to ER protein quality control [89] and ER to Golgi 
protein transport (Figure 17) [128,129]. It is however not clear what determines whether 
iRhom clients are exported or degraded [127]. Mutations in an iRhom coding gene have been 
shown to be linked with cancer [130]. 
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Figure 17: Schematic model of two functions of iRhoms in ER: ER to Golgi transport (top) 
and ERAD (bottom). Adopted from [127]. 
 
Derlins are in a more distant relationship with mammalian rhomboids than iRhoms 
(Figure 16) [131]. Their name originates from the first discovered derlin Der1 (degradation in 
the endoplasmic reticulum protein 1), which was discovered in S. cerevisiae [132]. This 
protein interacts with several ERAD-associated proteins [133], but the mechanistic details of 
its role in the ERAD process remain poorly understood. Its human ortholog, Derlin1, and its 
paralogs Derlin2 and 3 also play an important role in ERAD of many different proteins 
[134,135].   
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5 Aims of the study 
 
This work is a complex study of mechanism and specificity of intramembrane 
proteases from the rhomboid-like superfamily. It is focused on the main rhomboid model 
GlpG from the bacterium E. coli and on one of the four human secretase rhomboids, 
RHBDL2. GlpG was studied mainly in vitro to obtain detailed information about its substrate 
specificity, binding properties and kinetics parameters of the cleavage reaction, while 
RHBDL2 was studied in vivo with emphasis on its behavior in a natural biomembrane. 
 
Specific research aims: 
 Investigation of substrate binding, specificity and reaction mechanism of GlpG. 
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6.1 Substrate binding and specificity of rhomboid intramembrane protease 
revealed by substrate–peptide complex structures 
 
Background 
Rhomboid protease GlpG from the bacterium E. coli is intensively studied as the main 
model rhomboid for structural and mechanistic studies. The structure of this enzyme was well 
known, but our understanding of rhomboid mechanism was limited by the lack of information 
about the enzyme-substrate complex. To elucidate this, we determined X-ray structures of 
GlpG in co-crystals with peptidyl-chloromethylketone inhibitors derived from the natural 
rhomboid substrate TatA from P. stuartii. 
Summary 
Using biochemical analyses, we confirmed that binding of the peptidyl-
chloromethylketone inhibitor to GlpG is similar to substrate binding. With the help of X-ray 
crystallography, we identified the S1 to S4 subsites of the protease. We found that S1 subsite 
co-creates a cavity with the previously proposed water retention site. Surprisingly, the L1 
loop, which is a typical feature of rhomboids, helps create the S4 subsite. Its function may be 
similar also in other members of the rhomboid family. Finally, we created a molecular 
dynamics-based model of the Michaelis complex of GlpG with the substrate bound in the 
active site. 
My contribution 
I investigated GlpG specificity in vitro by conducting a complete positional scanning 
mutagenesis of the P5 to P1 region of the TatA substrate (Figure 18), analyzed the data and 
participated in writing of the relevant parts of the manuscript.  
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Figure 18: Specificity matrix of GlpG preferences on TatA variants in vitro. 
 
Substrate binding and specificity of rhomboid intramembrane protease revealed by substrate– 
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Martin Lepšík, Lucie Peclinovská, Pavel Majer, and Kvido Strisovsky (2014), The EMBO 































6.2 Sensitive versatile fluorogenic transmembrane peptide substrates for 
rhomboid intramembrane proteases 
 
Background 
Rhomboid-like superfamily is widespread and conserved in all domains of life. Its 
members participate in important biological processes like EGF receptor signaling, membrane 
protein quality control and mitochondrial dynamics. This makes them potential drug targets, 
but their potent and selective inhibitors were still missing. Unfortunately, current methods of 
studying rhomboid activity in vitro were incompatible with high-throughput screening and 
detailed kinetic analysis. To fill this gap, we designed a robust fluorogenic transmembrane 
peptide substrate platform for continuous activity assays. 
Summary 
We used the second transmembrane helix of the polytopic membrane protein LacY 
(LacYTM2) as a basis for the development of an internally quenched transmembrane 
fluorogenic substrate with positions P5 and P4’ replaced by Glu-EDANS and Lys-DABCYL. 
The LacYTM2 substrate was cleaved most efficiently by four diverse rhomboid proteases 
from all the tested model substrates. The fluorogenic transmembrane substrates derived from 
LacYTM2 can be used both in detergent micelles and in liposomes (Figure 19), without losing 
their helical structure. The use of the EDANS-DABCYL fluorophore-quencher pair and the 
red-shifted fluorophores such as carboxytetramethylrhodamine (TAMRA) makes these 
substrates applicable in high-throughput screening. Importantly, the cleavage efficiency and 
selectivity of this substrate can be dramatically increased by mutations of its residues at the P5 




Figure 19: Activity of GlpG in liposomes detected by the KSp35 fluorogenic substrate. 
 
My contribution 
I investigated the behavior and applicability of fluorogenic substrates in liposomes and 
I also cloned and purified some proteins used for the identification of the best starting 
substrate scaffold. I analyzed the results and participated in writing of relevant parts of the 
manuscript. 
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proteases. Anežka Tichá, Stancho Stanchev, Jan Škerle, Jakub Began, Marek Ingr, Kateřina 
Švehlová, Lucie Polovinkin, Martin Růžička, Lucie Bednárová, Romana Hadravová, Edita 
Poláchová, Petra Rampírová, Jana Březinová, Václav Kašička, Pavel Majer, and Kvido 
























6.3 General and modular strategy for designing potent, selective, and 
pharmacologically compliant inhibitors of rhomboid proteases  
 
Background 
Function of rhomboid proteases is associated with diseases like Parkinson’s disease, 
malaria and cancer. Their usage as therapeutic targets is limited by the lack of suitable 
inhibitors that could be used in biological studies and as templates for further drug 
development. To fill this gap in search for efficient rhomboid inhibitors, we tested inhibition 
potency of oligopeptides equipped with electrophilic warheads. 
Summary 
We discovered that peptidyl-α-ketoamides substituted at the ketoamide nitrogen by 
hydrophobic groups are potent rhomboid inhibitors active in the nanomolar range. These 
inhibitors bind the enzyme covalently, in a substrate-like manner, and the inhibition is 
selective and reversible. We also showed that excellent properties of these inhibitors, which 
work well also in vivo (Figure 20), can be tailored for individual rhomboid enzymes by an 
optimization of the peptide sequence and by choosing a suitable ketoamide substituent. Thus, 
we developed a platform for the design of specific and potent rhomboid inhibitors. 
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I participated in the development of an in vivo assay in permeabilized bacterial cells 
and participated in the characterization of some of the compounds both in vitro and in vivo. 
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Vinothkumar, David C. Mikles, Petr Pachl, Jakub Began, Jan Škerle, Kateřina Švehlová, Minh 
T.N. Nguyen, Steven H.L. Verhelst, Darren C. Johnson, Daniel A. Bachovchin, Martin 























































6.4 Membrane protein dimerization in cell-derived lipid membranes measured 
by FRET with MC simulations  
 
Background 
Limited information is available on the behaviour of proteins from rhomboid-like 
superfamily in native biomembranes. It has been published that rhomboid proteases dimerize 
in detergent micelles, which results in their allosteric activation [115], but information about 
their aggregation state in biomembranes has been absent. By combining several biophysical 
methods employing fluorescence reporters attached to proteins, we focused on both strong and 
weak interactions and we also excluded the potential effect of varying lipid composition in 
different cell compartments. 
Summary 
We used Foester resonance energy transfer (FRET) and fluorescence correlation 
spectroscopy (FCCS) combined with Monte Carlo (MC) simulation to address dimerization of 
human rhomboid protease RHBDL2 in its native biomembrane. Using this non-invasive 
approach, we found no evidence of rhomboid dimerization in membrane. By adapting methods 
commonly used for soluble proteins to 2D membrane environment, we developed a novel 
approach for membrane protein dimerization studies. To study the oligomeric state of 
RHBDL2 during its maturation in ER, our approach was also complemented by colocalization 
analysis of fluorescently labeled proteins (Figure 21). 
 
Figure 21: Localization of human rhomboid RHBDL2 in fusion with fluorescent protein on 
the plasma membrane. 
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My contribution 
I participated in planning and design of some of the experiments. I also designed and 
cloned most of the used constructs and performed a majority of the biological experiments. 
I participated in data analysis and writing of the manuscript. 
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Poláchová, Monika Fliegl, Jan Dohnálek, Anna Suchánková, David Jakubec, and Kvido 























































































7.1 Substrate binding, specificity and reaction mechanism of rhomboid protease 
GlpG 
 
The phenomenon of intramembrane proteolysis was first described about twenty years 
ago [7]. Since then, we have learn that this mechanism is linked with many important cell 
biological processes, from protein quality control and degradation [40] to cell proliferation 
[11] and differentiation [9], and also with many diseases like Parkinson’s disease [109] and 
cancer [108]. To develop effective drugs targeting intramembrane proteolysis we have to 
understand it mechanistically, and acquiring detailed information about substrate-enzyme 
interaction is key. To this end we have studied the main model intramembrane protease – E. 
coli GlpG from the rhomboid-like superfamily.  
With the help of X-ray crystallography, we have solved high-resolution structures of 
GlpG in complexes with peptidyl-chloromethylketone inhibitors. We have identified the 
substrate residues at P1 – P4 subsites which are crucial for substrate recognition and catalysis 
[102]. We have also demonstrated that the S4 subsite is formed by the L1 loop, which is 
highly conserved among rhomboids and function of which was unknown. We speculate that its 
role in the enzyme-substrate recognition and cleavage reaction is also conserved in other 
members of the rhomboid superfamily. The combination of our structural data and 
biochemical analyses with previously published work [136,137] enabled us to outline a model 
of enzyme-substrate complex, which showed an interaction between the P4 to P3’ segments of 
the substrate and the GlpG active site. Substrate residues at positions P4, P1 and P2’ strongly 
influence the kcat of the cleavage reaction, whereas they play minimal role in the substrate 
binding event, because the KM remains almost unaffected [136]. Taken together, the 
interaction interface between the enzyme and substrate is much larger than just the segment 
comprising residues at positions P4 to P2’ and this region of the substrate is responsible only 
for a small part of the total binding energy of the substrate. We significantly contributed to the 
clarification of the mechanism of substrate binding by rhomboid proteases. The full details of 
 127 
substrate recruitment by the enzyme, such as the structure of the transmembrane helix of the 
substrate bound to rhomboid, however, still remain to be elucidated.  
To build a structural model of GlpG with the full transmembrane domain of the 
substrate, we used an NMR structure of E. coli TatA [137]. Our model of the homologous P. 
stuartii TatA showed that its TMH is about 22 Å long, flanked by residues P13 and F27. In 
contrast, the thickness of the GlpG membrane portion is about 13 Å. Manual docking of this 
substrate TMH to the GlpG enzyme showed that a part of the TatA substrate TMD would stick 
out of the membrane (Figure 22). This situation is very unlikely due to the energy demand of 
such hydrophobic mismatch. Most probably, the substrate would try to avoid this by one of the 
two possible strategies. In the first case, the substrate TMD could be tilted or kinked to be 
completely hidden in the membrane; in this case the interaction of the transmembrane portion 
of the substrate with the enzyme would be minimal. In the second scenario, the substrate TMD 
could be curved and interact with GlpG to avoid interaction with the hydrophilic environment 
outside the membrane (Figure 22). The interface between GlpG and its substrate would thus 
be much larger in the second scenario, which is supported by our data and which would thus 
be more likely. In addition, similar behavior has been described for a region in a different 




Figure 22: Structural model of GlpG protease with the TatA substrate TMH. Three different 
possibilities of substrate TMH orientation within a membrane are distinguished by colors. 
Adopted from [139]. 
 
We propose that the interaction interface between the substrate and the enzyme is 
large, by showing the importance of the transmembrane region of the substrate for its 
recognition and catalysis using a series of C-terminally truncated transmembrane peptide 
substrates. These substrates are derivatives of LacYTM2, which is readily cleaved by diverse 
rhomboid proteases. These peptides were cleaved by the enzyme only in their full 
transmembrane versions, but their derivatives truncated by more than 5 residues from the 
transmembrane C-terminus were poorly utilized [140]. We tested whether LacYTM2 could 
also be used as a fluorogenic substrates when residues at the P5 and P4’ positions were 
modified by the EDANS/DABCYL FRET pair. These positions are not critical for rhomboid 
cleavage [102,139] and GlpG action was not affected by their mutations. The 7 amino acid 
residues distance between the two fluorophores is short enough for FRET to occur in the 
uncleaved substrate (EDANS is quenched by DABCYL) and cleavage is thus accompanied 
with an increase in fluorescence of EDANS. Such substrate can also be used in liposomes 
(Figure 19), where it is cleaved similarly as in detergent micelles. We also verified with CD 
spectroscopy that the helical structure of the TMH is unaffected. In addition, we 
experimentally confirmed that changing the sequence of the substrate according to GlpG 
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specificity [139] results in a more efficient GlpG-specific cleavage. By mutating all five 
residues at positions P5 to P1 of the fluorogenic LacYTM2 derivate, we reached 23-fold more 
efficient cleavage as compared to the wild type. We have also shown that by using this 
modification approach substrates can be easily adapted for efficient cleavage by different 
rhomboid proteases. 
Furthermore, we used the information about GlpG substrate specificity to generate 
a set of novel peptidyl-α-ketoamide inhibitors. We identified ketoamide as a promising 
electrophilic warhead, which exceeds other electrophilic reversibly binding warheads 
commonly used for serine proteases that we tested (trifluoromethylketones, boronates, 
acylsulfonamides, thiazolylketones) [141,142]. We experimentally confirmed that 
a modification of the peptidyl-α-ketoamides at their prime side of the active site increases their 
ability to inhibit rhomboids, presumably because the hydrophobic (in case of GlpG) P2’ 
residue of the substrate is important for rhomboid substrate recognition [102,136]. We have 
confirmed the selectivity of the peptidyl-α-ketoamides by a high-throughput assay for testing 
inhibitor potency and specificity [143], and a kinetic and structural analysis of our compounds 
revealed that they inhibit the rhomboid in a substrate-like manner and that the inhibition is 
covalent and reversible. They inhibited E. coli GlpG in vivo with up to 2 nM IC50. The 
inhibitors are modular because the peptidyl part of the inhibitor and the ketoamide warhead 
modification can be tailored separately, yielding selective inhibitors. In summary, we 
generated a new class of potent and selective rhomboid inhibitors that are superior to all other 
currently used rhomboid inhibitors and have a straightforward application in biology and drug 
discovery. 
 
7.2 Dimerization properties of membrane proteases from rhomboid family 
 
Dimerization of rhomboid proteases was reported as a mechanism regulating their 
activity in vitro [115]. However, this report was based only on experiments in a solubilized 
state in detergent micelles and the in vivo situation was not studied. The importance of this 
topic is confirmed by the fact that the same question was also addressed by other researchers. 
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Their observation is consistent with our results that the rhomboid behaves as a monomeric 
entity in natural lipid membrane [116]. By an integration of biophysical fluorescent techniques 
(FRET, FCCS), we focused on registration of strong and also weak interactions between two 
proteins. Our constructs of fluorescently labeled human rhomboid RHBDL2 were designed 
with respect to their usage on membrane surface (Figure 21). We paid special attention to the 
linker between the protein of interest and the fluorescent marker, as the distance between the 
fluorophores is one of FRET intensity determinants. We also needed to avoid 
misinterpretation and false positive results of FRET experiments caused by the ‘proximity 
effect’ [144] of overexpressed protein in high density. In the first place, we had the protein 
expression and localization under strict control and then we also used the Monte Carlo 
simulations to confirm the relevance of our observations. During its maturation, a membrane 
protein is exposed to varying lipid environment in different cellular organelles [145] and this 
can of course also affect the protein oligomeric state [146]. Taking this scenario into 
consideration, we also focused on the dimeric state of RHBDL2 in endoplasmic reticulum. 
Using this approach, we examined the oligomeric state of human rhomboid RHBDL2 under 
about 20-fold overexpression above physiological concentration, and we found no evidence of 
its dimerization in natural biomembranes after or during its maturation. This suggests, contrary 
to the current belief based on in vitro experiments, that dimerization may not be a universal 





In this work we focused on the mechanism, specificity and potential drug targeting of 
intramembrane proteases from the rhomboid family using biochemical and biophysical 
approaches. By X-ray crystallography combined with enzymatic assay and in silico modeling, 
we focused on the interaction between E. coli rhomboid protease GlpG and its substrate. We 
also used the non-invasive spectroscopic techniques FRET/FCCS in combination with MC 
simulations to investigate the oligomerization of human rhomboid RHBDL2 in native cell-
derived biomembranes.  
We elucidated the specificity of GlpG by positional scanning mutagenesis of rhomboid 
substrate TatA. Our observations confirmed the importance of substrate residues at positions 
P4 and P1. We found that some substrate mutations inhibit cleavage, but GlpG was also 
surprisingly more efficient in cleaving some mutant substrates. From our structural data on 
GlpG in complex with TatA-based peptidyl-chloromethylketone inhibitors, we identified the 
S1 to S4 subsites of the protease and elucidated the role of the conserved L1 loop, which co-
forms the S4 subsite. Furthermore, we used molecular dynamics to build a model of GlpG 
with the TatA substrate bound in its active site.  
We also focused on rhomboid proteases as potential therapeutic targets for inhibitor 
development. Detailed information about GlpG interaction with substrate helped us design 
a variety of fluorogenic substrates based on the sequence of the promiscuous rhomboid 
substrate TatATM2. By employing functional rhomboid cleavage assay, we confirmed the 
applicability of our fluorogenic substrates in the environment of detergent micelles and also in 
liposomes. Our substrates can be also easily adapted for different rhomboid proteases by 
mutating residues in the peptidyl part of the substrate at the P1 to P5 positions. By applying 
principles similar to those for the fluorogenic substrates, we further developed peptidyl-α-
ketoamide inhibitors of rhomboids. These inhibitors bind the enzyme in a substrate-like 
manner, covalently and reversibly. The inhibition is selective and the inhibitors work in 
nanomolar range. Their advantage is that they can be easily adapted to different rhomboid 
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proteases by inhibitor warhead modification and also by alteration of amino acid residues in 
the peptidyl part. 
We analyzed in vivo the behavior of human rhomboid RHBLD2. By spectroscopic 
techniques FCCS and FRET in combination with in vivo imagining of rhomboid localization 
and MC simulation, we investigated the tendency of rhomboid to dimerize. Although 
rhomboid dimerization and related activation was already described in detergent micelles in 
vitro, we found no evidence for occurrence of this phenomenon in vivo. The methodological 
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